Medicure Inc.

Medicure Inc.

March 29, 2005 09:00 ET

Medicure Expands Intellectual Patent Portfolio




MARCH 29, 2005 - 09:00 ET

Medicure Expands Intellectual Patent Portfolio

WINNIPEG, MANITOBA--(CCNMatthews - March 29, 2005) - Medicure Inc.
(TSX:MPH)(AMEX:MCU), a cardiovascular drug discovery and development
company, is pleased to announce the issuance of patent No. 6,867,215
"Cardioprotective Phosphonates and Malonates", by the US Patent and
Trademark Office. This new patent covers composition of matter claims
for Medicure's novel second generation anti-ischemic compounds for the
treatment of cardiovascular disease.

"This patent is an important addition to our global intellectual
property portfolio, and further demonstrates the strength of Medicure's
medicinal chemistry capabilities," said Albert D. Friesen, PhD,
Medicure's President and CEO. "Although our focus remains on our two
lead products, MC-1 and MC-4232, it is important for long term
shareholder value that we continue to expand our intellectual property
portfolio and product pipeline."

This patent further protects Medicure's intellectual property on
anti-ischemic compounds. Medicure's novel second generation
anti-ischemic compounds have demonstrated in vivo and in vitro efficacy
similar to Medicure's lead product MC-1. "Our second generation
anti-ischemic compounds are an integral element of our product pipeline.
Product life cycle management is a vital part of building a successful
biotechnology business, and the second generation anti-ischemics
strengthen our commercialization opportunities in the future," added Dr.


Medicure Inc. is a cardiovascular drug discovery and development Company
focused on developing effective therapeutics for unmet needs in the
field of cardiovascular medicine, the largest pharmaceutical market
sector. The Company's solid position in this field is supported by the
following attributes:

- Cardiovascular focused pipeline: a global market of over US $70 billion

- Two drugs - MC-1 & MC-4232 - in advanced Phase II trials

- Two positive Phase II trials completed

- Unique products addressing major markets not adequately served by
existing drugs

- Second combination product, MC-4262 is entering development stage

- Dual action antithrombotic, MC-45308, in preclinical testing

The Company's financial position remains solid, providing sufficient
resources to complete the ongoing Phase II studies, and to advance the
lead candidates up to pivotal Phase III studies.

Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule,
anti-ischemics and anti-thrombotics towards human clinical studies.

This press release contains forward-looking statements that involve
risks, which may cause actual results to differ materially from the
statements made, and accordingly may be deemed to be forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking statements
are made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.


Contact Information

    Medicure Inc.
    Derek Reimer
    Chief Financial Officer
    (888) 435-2220
    Medicure Inc.
    Hogan Mullally
    Manager of Investor & Public Relations
    (888) 435-2220
    (204) 488-9823 (FAX)